In summary while abrogation of S6K1 signalling has beneficial effects on ageing and age-related disease including attenuation of the pathology seen in AD, this therapeutic effect does not extend to the amelioration of the HD phenotype in the R6/2 mouse model of HD. This evidence concerns the gene RPS6KB1 and Huntington disease.